Longitudinal study of normal cognition in Parkinson disease
- PMID: 26362285
- PMCID: PMC4617168
- DOI: 10.1212/WNL.0000000000002001
Longitudinal study of normal cognition in Parkinson disease
Abstract
Objective: To report the rates and predictors of progression from normal cognition to either mild cognitive impairment (MCI) or dementia using standardized neuropsychological methods.
Methods: A prospective cohort of patients diagnosed with Parkinson disease (PD) and baseline normal cognition was assessed for cognitive decline, performance, and function for a minimum of 2 years, and up to 6. A panel of movement disorders experts classified patients as having normal cognition, MCI, or dementia, with 55/68 (80.9%) of eligible patients seen at year 6. Kaplan-Meier curves and Cox proportional hazard models were used to examine cognitive decline and its predictors.
Results: We enrolled 141 patients, who averaged 68.8 years of age, 63% men, who had PD on average for 5 years. The cumulative incidence of cognitive impairment was 8.5% at year 1, increasing to 47.4% by year 6. All incident MCI cases had progressed to dementia by year 5. In a multivariate analysis, predictors of future decline were male sex (p = 0.02), higher Unified Parkinson's Disease Rating Scale motor score (p ≤ 0.001), and worse global cognitive score (p < 0.001).
Conclusions: Approximately half of patients with PD with normal cognition at baseline develop cognitive impairment within 6 years and all new MCI cases progress to dementia within 5 years. Our results show that the transition from normal cognition to cognitive impairment, including dementia, occurs frequently and quickly. Certain clinical and cognitive variables may be useful in predicting progression to cognitive impairment in PD.
© 2015 American Academy of Neurology.
Figures
Comment in
-
Cognitive decline in Parkinson disease: How steep and crowded is the slope?Neurology. 2015 Oct 13;85(15):1268-9. doi: 10.1212/WNL.0000000000002003. Epub 2015 Sep 11. Neurology. 2015. PMID: 26362284 No abstract available.
References
-
- Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012;11:697–707. - PubMed
-
- Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837–844. - PubMed
-
- Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson's disease: results from an Italian cohort study. Parkinsonism Relat Disord 2011;17:265–269. - PubMed
Publication types
MeSH terms
Grants and funding
- P30-AG010124/AG/NIA NIH HHS/United States
- AG-19724/AG/NIA NIH HHS/United States
- NS053488/NS/NINDS NIH HHS/United States
- AG 029213/AG/NIA NIH HHS/United States
- P50 NS053488/NS/NINDS NIH HHS/United States
- P50-NS053488/NS/NINDS NIH HHS/United States
- K08 NS093127/NS/NINDS NIH HHS/United States
- AG 10124/AG/NIA NIH HHS/United States
- K23 AG034236/AG/NIA NIH HHS/United States
- UO1 NS082134/NS/NINDS NIH HHS/United States
- K23AG034236/AG/NIA NIH HHS/United States
- P01-AG017586/AG/NIA NIH HHS/United States
- AG 17586/AG/NIA NIH HHS/United States
- U01 NS082134/NS/NINDS NIH HHS/United States
- P01-AG032953/AG/NIA NIH HHS/United States
- AG 024904/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical